Clinical Trials Logo

Clinical Trial Summary

This pilot study is designed to investigate the effect of inhaled nitric oxide on cardiac, pulmonary artery, and systemic hemodynamics at various time points during venoarterial extracorporeal membrane oxygenation (VA-ECMO) support. Patients who have been initiated on VA-ECMO will be invited to participate. Inhaled nitric oxide (iNO) will be used early after VA-ECMO cannulation (once consent is obtained). After baseline hemodynamic, biochemical, and echocardiographic parameters are assessed, iNO will be initiated and all parameters will be reassessed after 30 minutes and 6 hours. Inhaled nitric oxide will then be discontinued and all parameters repeated. At the time of VA-ECMO weaning (timing determined by clinical team), iNO will be reinitiated with repeat assessment of hemodynamic, biochemical, and echocardiographic parameters both prior to the wean and after the wean (whether successful or not).


Clinical Trial Description

This is a proof of concept, pilot, phase II study using iNO in patients on VA-ECMO. Stage 1 will assess the participant's response to iNO early after cannulation. Stage 2 will assess the participant's response to iNO during the ECMO weaning process. Stage 1 Patients in whom VA-ECMO is being initiated will be invited to participate. Hemodynamic, echocardiographic, and biochemical parameters will be measured immediately prior to iNO administration and repeated 30 minutes after iNO initiation. iNO will be continued for six hours to allow hemodynamic and oxygenation parameters to stabilize as per previous protocols in the literature. After six hours, hemodynamic, echocardiographic, and biochemical parameters will be re-assessed after which iNO will be discontinued. All parameters will be re-evaluated 30 minutes after iNO discontinuation. Stage 2 A weaning trial will be performed at 1) the earliest signs of myocardial recovery or b) day 5. Myocardial recovery will be defined as: mean arterial pressure > 60 millimeters of mercury (mmHg) on no or minimal inotropic/vasopressor support, arterial pulse pressure > 10 mmHg, and minimal respiratory support (oxygen saturation > 88% on < 2 liters by nasal cannulae, or minimal ventilator setting if intubated). Inhaled nitric oxide will be re-initiated 30 minutes prior to the ECMO weaning trial. Adequacy of perfusion will be defined as a mixed venous oxygen saturation of > 70%. Hemodynamic, echocardiographic, and biochemical parameter will be recorded immediately prior to iNO administration and then at 30 minutes prior to the ECMO weaning trial. ECMO will be weaned as per the standard protocol at the University Health Network with re-assessment of all parameters after weaning is complete. When ECMO weaning is unsuccessful, these parameters will be recorded immediately prior to re-initiation of full flow VA-ECMO and 30 minutes thereafter. VA-ECMO weaning will be re-attempted at 24-48 hours at the discretion of the medical team. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04224103
Study type Observational
Source University of Toronto
Contact Andrea L Daly, MD
Phone 16475457454
Email andrealdaly@gmail.com
Status Recruiting
Phase
Start date August 8, 2019
Completion date February 28, 2022

See also
  Status Clinical Trial Phase
Completed NCT03685383 - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation N/A
Not yet recruiting NCT05106491 - Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients N/A
Recruiting NCT05699005 - Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO Phase 1
Recruiting NCT05444764 - PREdiCtIon of Weanability, Survival and Functional outcomEs After ECLS
Completed NCT05038943 - Evaluation of Safety and Effectiveness of The SherpaPak in Donation After Circulatory Death Heart Transplantation N/A
Not yet recruiting NCT05341687 - Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Recruiting NCT03766282 - Pharmacokinetics in Extracorporeal Membrane Oxygenation
Completed NCT03355625 - Platelet Function During Extracorporeal Membrane Oxygenation in Adult Patients
Completed NCT01521195 - Oxygen Consumption In Critically Ill Children N/A
Recruiting NCT04620070 - ON-SCENE Initiation of Extracorporeal CardioPulmonary Resuscitation During Refractory Out-of-Hospital Cardiac Arrest N/A
Recruiting NCT06062212 - Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO
Recruiting NCT05730114 - Monitoring Antiplatelet Drugs in Cardiac Arrest Patients
Completed NCT05154071 - Impact of the Implementation of a Referral Veno-venous Extracorporeal Membrane Oxygenation Centre on Mortality
Recruiting NCT04536272 - Reduced Anticoagulation Targets in ECLS (RATE) Phase 3
Completed NCT05693051 - Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO
Completed NCT03764319 - Low Frequency, Ultra-low Tidal Volume Ventilation in Patients With ARDS and ECMO N/A
Recruiting NCT05762029 - Treatment of Extracorporeal Membrane Oxygenation in Severe Poisoning
Completed NCT02995811 - Characterising Changes in Muscle Quantity and Quality in Patients Requiring ECMO Oxygen During Critical Illness
Recruiting NCT04754854 - Reduction of Blood Recirculation in Veno-Venous ECMO